Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DA-1229_01 (Evogliptin/Metformin XR) vs Co-administration in Healthy Males
NCT02375139Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Apr 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA5221-B2 and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area Under Curve (AUC) last at 72 hours and Maximum Concentration at 72 hours. Started Apr 2015; status: completed.
02
Drugs
DA5221-B2metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02375139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375139.